| Literature DB >> 33925518 |
David McConnell1,2, Conor Hickey1,2, Norma Bargary3, Lea Trela-Larsen1,2, Cathal Walsh1,3, Michael Barry1,2, Roisin Adams1,2.
Abstract
SARS-CoV-2 continues to widely circulate in populations globally. Underdetection is acknowledged and is problematic when attempting to capture the true prevalence. Seroprevalence studies, where blood samples from a population sample are tested for SARS-CoV-2 antibodies that react to the SARS-CoV-2 virus, are a common method for estimating the proportion of people previously infected with the virus in a given population. However, obtaining reliable estimates from seroprevalence studies is challenging for a number of reasons, and the uncertainty in the results is often overlooked by scientists, policy makers, and the media. This paper reviews the methodological issues that arise in designing these studies, and the main sources of uncertainty that affect the results. We discuss the choice of study population, recruitment of subjects, uncertainty surrounding the accuracy of antibody tests, and the relationship between antibodies and infection over time. Understanding these issues can help the reader to interpret and critically evaluate the results of seroprevalence studies.Entities:
Keywords: COVID-19; SARS-CoV-2; antibody testing; coronavirus; seroprevalence
Mesh:
Substances:
Year: 2021 PMID: 33925518 DOI: 10.3390/ijerph18094640
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390